Molbio Diagnostics Q2 FY27 Results: Income Declines 54% YoY to ₹265 Cr, PAT Drops to ₹8 Cr
Molbio Diagnostics reported Q2 FY27 total income of ₹265 Cr, down 54% YoY from ₹581.4 Cr. PAT fell to ₹8 Cr from ₹106.8 Cr. H1 FY27 income was ₹676 Cr, slightly down from ₹681.8 Cr in H1 FY26. Management cited rate negotiations affecting Q2 sales but maintained a FY27 topline growth guidance of 25%.
The substantial drop in quarterly revenue and profit directly impacts the company's financial health and investor sentiment, making the impact high.
The company reported a significant year-on-year decline in total income and profit after tax for the quarter ended September 30, 2026, indicating a negative financial performance.
Molbio Diagnostics Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a total income of ₹265 crore for Q2 FY27, a significant decrease from ₹581.4 crore in Q2 FY26. Profit After Tax (PAT) for the quarter stood at ₹8 crore, down from ₹106.8 crore in the corresponding period last year. The EBITDA margin for Q2 FY27 was 18.8%, compared to 29.0% in Q2 FY26.
For the half-year ended September 30, 2026 (H1 FY27), total income was ₹676 crore, a slight decrease from ₹681.8 crore in H1 FY26. PAT for H1 FY27 was ₹60 crore, down from ₹82.9 crore in H1 FY26. The EBITDA margin for H1 FY27 was 22.7%, largely flat compared to 22.5% in H1 FY26.
Management commentary indicated that the softer performance in Q2 FY27 was due to ongoing rate negotiations which impacted sales for a full three months. The company reiterated its guidance of 25% topline growth in FY27 over FY26 and highlighted progress in expanding global presence and strengthening its R&D portfolio. New platforms are under development, and radiology products are being deployed for veterinary use, with six new veterinary assays in development.
What to do with a filing like this
Molbio Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Molbio Diagnostics Limited. Read the original for the full detail.